menu
    • menu
    [{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Ultragenyx"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Jefferies"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"9","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Setrusumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Setrusumab

    Menu

    Setrusumab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ultragenyx Receives Breakthrough Designation For Setrusumab in Osteogenesis Imperfecta

                            Details : UX143 (setrusumab), is a sclerostin inhibitor antibody drug candidate, which is currently being evaluated for the treatment of osteogenesis imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 07, 2024

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Mereo BioPharma Prices $50 Million Direct Offering of American Depository Shares

                            Details : The net proceeds will be used to fund the clinical advancement of the BPS804 (setrusumab), a monoclonal antibody that is being investigated for the potential treatment of Osteogenesis Imperfecta.

                            Brand Name : BPS804

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 14, 2024

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Jefferies

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $350.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ultragenyx Prices Public Offering Of Common Stock, Pre-Funded Warrants

                            Details : The net proceeds of the offering to continue to advance the late-stage clinical program UX143 (setrusumab), which is being evaluated for the treatment of osteogenesis imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 13, 2024

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $350.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Mereo BioPharma Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ultragenyx & Mereo BioPharma: New Phase 2 Data on Setrusumab in Osteogenesis Imperfecta

                            Details : UX143 (setrusumab), is a sclerostin inhibitor antibody drug candidate, which is currently being evaluated for the treatment of osteogenesis imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 11, 2024

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Mereo BioPharma Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ultragenyx Completes Enrollment in Setrusumab Studies for Osteogenesis Imperfecta

                            Details : UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a critical protein in bone-signaling pathways affecting bone-forming cell maturation in osteogenesis imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 30, 2024

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $326.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of U...

                            Details : The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into cl...

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 23, 2023

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $326.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

                            Details : The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into cl...

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $300.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ultragenyx Announces Proposed Public Offering of Common Stock

                            Details : The proceeds will advance company's late-stage clinical programs, including UX143 (setrusumab), an investigational, fully human mAb that inhibits sclerostin, support commercial launch, and advance its preclinical pipeline through IND applications into cl...

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 17, 2023

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : J.P. Morgan

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Mereo BioPharma Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusum...

                            Details : UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 14, 2023

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Mereo BioPharma Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Ultragenyx Pharmaceutical

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment o...

                            Details : UX143 (setrusumab) is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the maturation and activity of bone-forming cells in Osteogenesis Imperfecta.

                            Brand Name : UX143

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 06, 2023

                            Lead Product(s) : Setrusumab

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth